logo-loader
viewCytoDyn Inc.

CytoDyn shows value of company lies in their research and technology

CytoDyn (OTCMKTS:CYDY) President and CEO Nader Pourhassan and Chairman and Chief Medical Officer Dr Richard Pestell joined Proactive Investors' Steve Darling during the 9th Annual LD Micro Invitational Investor Conference in Los Angeles, CA.  Both talked about the company and where they are in the research on HIV and Triple Negative Breast Cancer.

Quick facts: CytoDyn Inc.

Price: 1.37 USD

OTCMKTS:CYDY
Market: OTCQB
Market Cap: $590.14 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of CytoDyn Inc. named herein, including the promotion by the Company of CytoDyn Inc. in any Content on the Site, the Company receives from said...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Full interview: CytoDyn files modified protocol for Leronlimab trial...

CytoDyn (OTCQB: CYDY) President and CEO Nader Pourhassan joined Steve Darling from Proactive Vancouver to discuss the company filing a modified protocol of their Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Leronlimab in Patients with...

2 weeks ago

2 min read